EAM
FDMT icon

Exome Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Exome Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22M Buy
+130,564
New +$1.14M 0.63% 48

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Exome Asset Management's FDMT Position: Q1 2026 in Review

Exome Asset Management opened a new position in 4D Molecular Therapeutics (FDMT) in Q1 2026: 130,564 shares worth $1.22M. The stake represents 0.63% of the portfolio and ranks #48 among its holdings.

152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Exome Asset Management held 130,564 shares of 4D Molecular Therapeutics worth $1.22M as of Q1 2026.
  • 4D Molecular Therapeutics was a new Exome Asset Management position in Q1 2026.
  • 4D Molecular Therapeutics made up 0.63% of Exome Asset Management's portfolio in Q1 2026, its #48 holding.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.